Skip to main content

Advertisement

SpringerLink
Log in

Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

The therapeutic landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has changed dramatically. Here, we provide the current status and future prospective of the management of mHSPC.

Methods

We reviewed recent literature of landmark studies on the managements of mHSPC.

Results

Upfront docetaxel or androgen receptor signaling inhibitor (ARSi) in addition to ADT has improved survival in mHSPC patients and has become the new standard of care. Triplet therapy with docetaxel, ARSi and ADT also improved survival. In the future, triplet therapy may become the standard of care. Oligometastatic mHSPC patients could benefit from local therapy. The inclusion of risk factors or the genetic biomarkers will provide the best treatment for individual mHSPC patients.

Conclusion

Strong systemic therapy in the first-line treatment of mHSPC has been shown to improve survival and quality of life. Currently, several clinical trials are evaluating novel compounds such as PARP inhibitor, AKT inhibitor, and immune checkpoint inhibitor. The therapeutic landscape of mHSPC management will change dramatically.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Huggins C, Stevens RE Jr, Hodges CV (1941) Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43(2):209–223. https://doi.org/10.1001/archsurg.1941.01210140043004

    Article  CAS  Google Scholar 

  2. Bubley GJ, Balk SP (1996) Treatment of androgen-independent prostate cancer. Oncologist 1(1):30–35. https://doi.org/10.1634/theoncologist.1-1-30

    Article  CAS  PubMed  Google Scholar 

  3. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G et al (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188(4):1164–1169. https://doi.org/10.1016/j.juro.2012.06.046

    Article  PubMed  PubMed Central  Google Scholar 

  4. Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G et al (1982) New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5(4):267–275

    CAS  PubMed  Google Scholar 

  5. (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Prostate Cancer Trialists’ Collaborative Group. Lancet. 355(9214):1491–1498 https://doi.org/10.1016/S0140-6736(00)02163-2

  6. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746. https://doi.org/10.1056/NEJMoa1503747

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149–158. https://doi.org/10.1016/j.urolonc.2013.08.011

    Article  CAS  PubMed  Google Scholar 

  8. Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F et al (2016) Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 70(2):256–262. https://doi.org/10.1016/j.eururo.2015.11.005

    Article  CAS  PubMed  Google Scholar 

  9. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase. J Clin Oncol 36(11):1080–1084. https://doi.org/10.1200/JCO.2017.75.3657

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163–1177. https://doi.org/10.1016/S0140-6736(15)01037-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G et al (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 30(12):1992–2003. https://doi.org/10.1093/annonc/mdz396

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA et al (2018) Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 73(6):847–855. https://doi.org/10.1016/j.eururo.2018.02.001

    Article  PubMed  PubMed Central  Google Scholar 

  13. Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA et al (2018) Quality of life during treatment with chemo-hormonal therapy: analysis of E3805 chemo-hormonal androgen ablation randomized trial in prostate cancer. J Clin Oncol 36(11):1088–1095. https://doi.org/10.1200/JCO.2017.75.3335

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360. https://doi.org/10.1056/NEJMoa1704174

    Article  CAS  PubMed  Google Scholar 

  15. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686–700. https://doi.org/10.1016/S1470-2045(19)30082-8

    Article  CAS  PubMed  Google Scholar 

  16. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338–351. https://doi.org/10.1056/NEJMoa1702900

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37(32):2974–2986. https://doi.org/10.1200/JCO.19.00799

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J et al (2022) Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 40(15):1616–1622. https://doi.org/10.1200/JCO.22.00193

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381(2):121–131. https://doi.org/10.1056/NEJMoa1903835

    Article  CAS  PubMed  Google Scholar 

  20. Chi KN, Agarwal N, Bjartell A, Chung BH, de Santana P, Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13–24. https://doi.org/10.1056/NEJMoa1903307

    Article  CAS  PubMed  Google Scholar 

  21. Chi KN, Chowdhury S, Bjartell A, Chung BH, de Santana P, Gomes AJ, Given R et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39(20):2294–2303. https://doi.org/10.1200/JCO.20.03488

    Article  CAS  PubMed  Google Scholar 

  22. Fizazi K, Foulon S, Carles J, Roubaud G, McDermott RS, Flechon A et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet S1040–6736(22):00367–00371. https://doi.org/10.1016/S0140-6736(22)00367-1

    Article  Google Scholar 

  23. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386(12):1132–1142. https://doi.org/10.1056/NEJMoa2119115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD Trial. Eur Urol 75(3):410–418. https://doi.org/10.1016/j.eururo.2018.09.008

    Article  PubMed  Google Scholar 

  25. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353–2366. https://doi.org/10.1016/S0140-6736(18)32486-3

    Article  PubMed  PubMed Central  Google Scholar 

  26. Burdett S, Boeve LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL et al (2019) Prostate radiotherapy for metastatic hormone sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol 76(1):115–124. https://doi.org/10.1016/j.eururo.2019.02.003

    Article  PubMed  PubMed Central  Google Scholar 

  27. Fujita K, Nonomura N (2019) Role of androgen receptor in prostate cancer: a review. World J Mens Health 37(3):288–295. https://doi.org/10.5534/wjmh.180040

    Article  PubMed  Google Scholar 

  28. Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA et al (2019) Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment naïve primary prostate cancer. Clin Cancer Res 25(22):6721–6730. https://doi.org/10.1158/1078-0432.CCR-19-1587

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hamid AA, Huang HC, Wang V, Chen YH, Feng F, Den R et al (2021) Transcriptional profiling of primary prostate tumor in metastatic hormone sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol 32(9):1157–1166. https://doi.org/10.1016/j.annonc.2021.06.003

    Article  CAS  PubMed  Google Scholar 

  30. Feng FY, Thomas S, Aguilar-Bonavides C, Gormley M, Agarwal N, Attard G et al (2020) Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN. J Clin Oncol 38(15):5535. https://doi.org/10.1200/JCO.2020.38.15_suppl.5535

    Article  Google Scholar 

Download references

Funding

The research did not receive any specific grant from any founding agency in the public, commercial, or not-for-profit sector.

Author information

Authors and Affiliations

  1. Department of Urology, Mimihara General Hospital, 4-465, Kyowacho, Sakai Sakai-ku, Osaka, 590-8505, Japan

    Naoki Matsumura & Hideo Tahara

  2. Department of Urology, Faculty of Medicine, Kindai University Hospital, 377-2, Onohigashi, Osakasayama, Osaka, 589-8511, Japan

    Kazutoshi Fujita, Mitsuhisa Nishimoto, Takafumi Minami, Kazuhiro Yoshimura & Hirotsugu Uemura

Authors
  1. Naoki Matsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazutoshi Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitsuhisa Nishimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takafumi Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideo Tahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiro Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirotsugu Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Writing—original draft preparation: NM. Conceptualization: KF. Review and editing: KF, MN, TM, HT, KY and HU.

Corresponding author

Correspondence to Kazutoshi Fujita.

Ethics declarations

Conflict of interest

K.F. and H.U. received Honoria from Jansen, Astellas, AstraZeneca, and Bayer.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This article does not contain any studies with human participants. Therefore, issues of informed consent are not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matsumura, N., Fujita, K., Nishimoto, M. et al. Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer. World J Urol 41, 2063–2068 (2023). https://doi.org/10.1007/s00345-022-04134-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-022-04134-9

Keywords

Search

Navigation